49464 Federal Register / Vol. 73, No. 163 / Thursday, August 21, 2008 / Notices 

Exhibit 2 shows the estimated 

annualized cost burden for the 

respondents. The Bureau of Labor 

Statistics reported that the average 

hourly wage for ‘‘healthcare practitioner 

and technical occupations’’ in the 

United States was $29.82 in May 2006. 

An estimate of $30 per hour allows for 

inflation and represents a conservative 

estimate of the wages of the 

respondents. Therefore, the total 

estimated cost burden for respondents is 

$12,030, based on the total estimated 

annualized burden of 401 hours. 

EXHIBIT 2—ESTIMATED ANNUALIZED COST BURDEN

Form name Number of 

respondents 

Total burden 

hours 

Average hourly wage rate * Total cost 

burden 

E-mail submission ............................................................................................ 41 21 $30 $630 

Health care innovator interview—following e-mail submission ....................... 41 21 30 630 

Health care innovator interview without e-mail submission ............................ 234 234 30 7,020 

Annual follow-up interview ............................................................................... 250 125 30 3,750 

Total .......................................................................................................... 566 401 ........................ 12,030 

* Based upon the average wages, ‘‘National Compensation Survey: Occupational Wages in the United States, May 2006,’’ U.S. Department of 

Labor, Bureau of Labor Statistics. 

Estimated Annual Costs to the Federal 

Government 

The total cost to the Government is 

approximately $3,349,560 over three 

years (on average, $1,116,520 per year). 

These costs cover the total editorial and 

content development processes 

associated with the project; which 

include developing an on-line authoring 

tool for preparing the profiles, 

identifying innovation leads, reviewing 

e-mail submissions, contacting the 

innovators, conducting interviews, 

preparing the draft profiles, securing 

innovator approval, and publishing the 

profiles on the Innovations Exchange 

Web site. 

Request for Comments 

In accordance with the above-cited 

Paperwork Reduction Act legislation, 

comments on AHRQ’s information 

collection are requested with regard to 

any of the following: (a) Whether the 

proposed collection of information is 

necessary for the proper performance of 

AHRQ health care research, quality 

improvement and information 

dissemination functions, including 

whether the information will have 

practical utility; (b) the accuracy of 

AHRQ’s estimate of burden (including 

hours and costs) of the proposed 

collection(s) of information; (c) ways to 

enhance the quality, utility, and clarity 

of the information to be collected; and 

(d) ways to minimize the burden of the 

collection of information upon the 

respondents, including the use of 

automated collection techniques or 

other forms of information technology. 

Comments submitted in response to 

this notice will be summarized and 

included in the Agency’s subsequent 

request for OMB approval of the 

proposed information collection. All 

comments will become a matter of 

public record. 

Dated: August 12, 2008. 

Carolyn M. Clancy, 

Director. 

[FR Doc. E8–19302 Filed 8–20–08; 8:45 am] 

BILLING CODE 4160–90–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Administration for Children and 

Families 

Submission for OMB Review; 

Comment Request 

Title: State Plan for the Temporary 

Assistance for Needy Families (TANF). 

OMB No.: 0970–0145. 

Description: The State plan is a 

mandatory statement submitted to the 

Secretary of the Department of Health 

and Human Services by the State. It 

consists of an outline of how the States 

TANF program will be administered 

and operated and certain required 

certifications by the States Chief 

Executive Officer. Its submittal triggers 

the States family assistance grant 

funding and it is used to provide the 

public with information about the 

program. If a State makes changes in its 

program, it must submit a State plan 

amendment. 

Respondents: The 50 States, the 

District of Columbia, Guam, Puerto Rico 

and the Virgin Islands. 

ANNUAL BURDEN ESTIMATES

Instrument Number of respondents 

Number of responses per 

respondent 

Average burden hours per 

response 

Total burden 

hours 

Temporary Assistance to Needy Families State Plan Guidance .................... 54 0.50 33 891 

Estimated Total Annual Burden 

Hours: 891. 

Additional Information: Copies of the 

proposed collection may be obtained by 

writing to the Administration for 

Children and Families, Office of 

Administration, Office of Information 

Services, 370 L’Enfant Promenade, SW., 

Washington, DC 20447, Attn: ACF 

Reports Clearance Officer. All requests 

should be identified by the title of the 

information collection. E-mail address: 

infocollection@acf.hhs.gov. 

OMB Comment: OMB is required to 

make a decision concerning the 

collection of information between 30 

and 60 days after publication of this 

document in the Federal Register. 

Therefore, a comment is best assured of 

having its full effect if OMB receives it 

within 30 days of publication. Written 

comments and recommendations for the 

proposed information collection should 

be sent directly to the following: Office 

of Management and Budget, Paperwork 

Reduction Project, Fax: 202–395–6974, 

Attn: Desk Officer for the 

Administration for Children and 

Families. 

mstockstill on PROD1PC66 with NOTICES

Federal Register / Vol. 73, No. 163 / Thursday, August 21, 2008 / Notices 49465 

Dated: August 14, 2008. 

Robert Sargis, 

Reports Clearance Officer. 

[FR Doc. E8–19220 Filed 8–20–08; 8:45 am] 

BILLING CODE 4184–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2008–N–0039] 

Chloramine-T for Control of Bacterial 

Gill Disease in Freshwater-Reared 

Salmonids; Availability of Data 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

SUMMARY: The Food and Drug 

Administration (FDA) is announcing the 

availability of effectiveness and target 

animal safety data that may be used in 

support of a new animal drug 

application (NADA) or supplemental 

NADA for use of chloramine-T by 

immersion for the control of mortality in 

freshwater-reared salmonids due to 

bacterial gill disease. The data, 

contained in Public Master File (PMF) 

5893, were compiled by the U.S. 

Department of the Interior, U.S. Fish 

and Wildlife Service, Aquatic Animal 

Drug Approval Partnership Program. 

ADDRESSES: Submit NADAs or 

supplemental NADAs to the Document 

Control Unit (HFV–199), Center for 

Veterinary Medicine, Food and Drug 

Administration, 7500 Standish Pl., 

Rockville, MD 20855. 

FOR FURTHER INFORMATION CONTACT: 

Donald A. Prater, Center for Veterinary 

Medicine (HFV–130), Food and Drug 

Administration, 7500 Standish Pl., 

Rockville, MD 20855, 240–276–8343, email: donald.prater@fda.hhs.gov. 

SUPPLEMENTARY INFORMATION: 

Chloramine-T used by immersion for 

control of mortality in freshwater-reared 

salmonids due to bacterial gill disease is 

a new animal drug under section 201(v) 

of the Federal Food, Drug, and Cosmetic 

Act (the act) (21 U.S.C. 321(v)). As a 

new animal drug, chloramine-T is 

subject to section 512 of the act (21 

U.S.C. 360b) which requires that its uses 

be the subject of an approved NADA or 

supplemental NADA. Fish are a minor 

species under § 514.1(d)(1)(ii) (21 CFR 

514.1(d)(1)(ii)). 

The U.S. Department of the Interior, 

U.S. Fish and Wildlife Service, Aquatic 

Animal Drug Approval Partnership 

Program, 4050 Bridger Canyon Rd., 

Bozeman, MT 59715, has provided 

effectiveness and target animal safety 

data for use of chloramine-T by 

immersion for control of mortality in 

freshwater-reared salmonids due to 

bacterial gill disease. These data are 

contained in PMF 5893. 

Sponsors of NADAs or supplemental 

NADAs may, without further 

authorization, reference the PMF 5893 

to support approval of an application 

filed under § 514.1(d). An NADA or 

supplemental NADA must include, in 

addition to reference to the PMF, animal 

drug labeling and other information 

needed for approval, such as: data 

concerning human food safety; and 

manufacturing methods, facilities, and 

controls. Persons desiring more 

information concerning PMF 5893 or 

requirements for approval of an NADA 

or supplemental NADA may contact the 

Center for Veterinary Medicine (see FOR

FURTHER INFORMATION CONTACT). 

In accordance with the freedom of 

information provisions of 21 CFR part 

20, a summary of safety and 

effectiveness data provided in PMF 

5893 to support approval of an 

application may be seen in the Division 

of Dockets Management (HFA–305), 

Food and Drug Administration, 5630 

Fishers Lane, rm. 1061, Rockville, MD 

20852, from 9 a.m. to 4 p.m., Monday 

through Friday. 

Dated: August 8, 2008. 

Bernadette Dunham, 

Director, Center for Veterinary Medicine. 

[FR Doc. E8–19299 Filed 8–20–08; 8:45 am] 

BILLING CODE 4160–01–S 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Shared 

Instrumentation (S10) Review. 

Date: September 8, 2008. 

Time: 8:30 a.m. to 4 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hyatt Regency O’Hare, 9300 Bryn 

Mawr Avenue, Rosemont, IL 60018. 

Contact Person: Barbara Whitmarsh, PhD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 2206, 

MSC 7890, Bethesda, MD 20892, (301) 435–

4511, whitmarshb@csr.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

Name of Committee: Cell Biology 

Integrated Review Group Intercellular 

Interactions Study Section. 

Date: September 22–23, 2008. 

Time: 8:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: George Washington University Inn, 

824 New Hampshire Avenue, NW., 

Washington, DC 20037. 

Contact Person: David Balasundaram, PhD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5189, 

MSC 7840, Bethesda, MD 20892, 301–435–

1022, balasundaramd@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Applications Related to Dementia, Substance 

Abuse, or Behavioral Development. 

Date: September 24, 2008. 

Time: 2 p.m. to 4 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892 

(Telephone Conference Call). 

Contact Person: Ellen K. Schwartz, EDD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3168, 

MSC 7770, Bethesda, MD 20892, 301–435–

0681, schwarte@csr.nih.gov. 

Name of Committee: Bioengineering 

Sciences & Technologies Integrated Review 

Group; Biomaterials and Biointerfaces Study 

Section. 

Date: September 25, 2008. 

Time: 8 a.m. to 6 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Doubletree Hotel Bethesda, 8120 

Wisconsin Avenue, Bethesda, MD 20814. 

Contact Person: Ross D. Shonat, PhD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5156, 

MSC 7849, Bethesda, MD 20892, 301–435–

2786, shonatr@csr.nih.gov. 

Name of Committee: Bioengineering 

Sciences & Technologies Integrated Review 

Group; Nanotechnology Study Section. 

Date: September 30–October 1, 2008. 

Time: 8:30 a.m. to 6 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hilton Alexandria Old Town, 1767 

King Street, Alexandria, VA 22314. 

Contact Person: Joseph D. Mosca, PhD, 

Scientific Review Officer, Center for 

mstockstill on PROD1PC66 with NOTICES